Kush M Parmar, MD, PhD is a Managing Partner at 5AM Ventures. Dr. Parmar is a Director on the Boards of Ensoma, GlycoEra, Precede Bioscience, and Rallybio. He previously served as Board Member or Observer for Achaogen, Akouos (acquired by Eli Lilly), Arvinas, Audentes (acquired by Astellas), Envoy (acquired by Takeda), Homology, scPharmaceuticals, Vor Biopharma, and as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J).
Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995).
Dr. Parmar holds an AB in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University and an MD from Harvard Medical School.
What is Kush Parmar's net worth?
The estimated net worth of Kush Parmar is at least $30.10 million as of November 14th, 2025. Parmar owns 2,963,066 shares of Entrada Therapeutics stock worth more than $30,104,751 as of December 5th. This net worth estimate does not reflect any other investments that Parmar may own. Learn More about Kush Parmar's net worth.
How do I contact Kush Parmar?
Has Kush Parmar been buying or selling shares of Entrada Therapeutics?
During the past quarter, Kush Parmar has sold $1,760,000.00 of Entrada Therapeutics stock. Most recently, Kush Parmar sold 200,000 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $8.80, for a transaction totalling $1,760,000.00. Following the completion of the sale, the director now directly owns 2,963,066 shares of the company's stock, valued at $26,074,980.80. Learn More on Kush Parmar's trading history.
Who are Entrada Therapeutics' active insiders?
Are insiders buying or selling shares of Entrada Therapeutics?
In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 685,845 shares worth more than $5,867,281.75. The most recent insider tranaction occured on November, 21st when CFO Kory James Wentworth sold 8,910 shares worth more than $88,921.80. Insiders at Entrada Therapeutics own 8.1% of the company.
Learn More about insider trades at Entrada Therapeutics. Information on this page was last updated on 11/21/2025.
